enasidenib   Click here for help

GtoPdb Ligand ID: 8960

Synonyms: AG-221 | CC-90007 | Idhifa®
Approved drug PDB Ligand
enasidenib is an approved drug (FDA (2017))
Compound class: Synthetic organic
Comment: Enasidenib (AG-221) is an orally available inhibitor of isocitrate dehygrogenase 2 (IDH2), that is approved as an antineoplastic agent. This compound is example 409 in patent US20130190287 A1 [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 108.74
Molecular weight 473.14
XLogP 3.02
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)c1cccc(n1)C(F)(F)F)(O)C
Isomeric SMILES CC(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)c1cccc(n1)C(F)(F)F)(O)C
InChI InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
InChI Key DYLUUSLLRIQKOE-UHFFFAOYSA-N
References
1. Cianchetta G, Delabarre B, Popovici-Muller J, Salituro FG, Saunders JO, Travins J, Yan S, Guo T, Zhang L. (2013)
Therapeutically active compounds and their methods of use.
Patent number: US20130190287 A1. Assignee: Agios Pharmaceuticals, Inc.. Priority date: 06/01/2012. Publication date: 25/07/2013.
2. Kim ES. (2017)
Enasidenib: First Global Approval.
Drugs, 77 (15): 1705-1711. [PMID:28879540]